To include your compound in the COVID-19 Resource Center, submit it here.

Esperion to raise funds after reporting bempedoic acid LDL-C data

Esperion Therapeutics Inc. (NASDAQ:ESPR) proposed to raise $150 million in a follow-on after market close on Tuesday following its announcement earlier in the day that oral bempedoic acid (ETC-1002)/Zetia ezetimibe plus Lipitor atorvastatin met the primary endpoint of reducing LDL-C compared to placebo in a Phase

Read the full 465 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE